Background Nanocarrier platforms have been indicated to have great potential in clinical
practice to treat non-small cell lung cancer (NSCLC). Our previous Phase III clinical study …

Melanoma, the most malignant form of skin cancer, shows resistance to traditional
anticancer drugs including paclitaxel (PTX). Furthermore, over 50% of melanoma cases …

Neuroblastoma, a neoplasm of the sympathetic nervous system, is the second most common
extracranial malignant tumor of childhood and the most common solid tumor of infancy …

The objective of this study was to overcome drug resistance upon systemic administration of
combination paclitaxel (PTX) and the apoptotic signaling molecule C6‐ceramide (CER) in …

Paclitaxel is a widely used anti-tumor chemotherapeutic drug. Solvent-based paclitaxel
causes bone marrow suppression, allergic reactions, neurotoxicity and systemic toxicity …

Multidrug resistance (MDR) is a main clinical hurdle for chemotherapy of cancer, and
overexpression of P-glycoprotein (P-gp) is a key factor. In the present study, a new co …

Paclitaxel (PTX), an antimicrotubular agent used in the treatment of ovarian and breast
cancer, was encapsulated in nanoparticles (NPs) of poly (lactide-co-glycolide)(PLGA) and …

Strategies for the development of anticancer drug delivery systems have undergone a
dramatic transformation in the last few decades. Lipid-based drug delivery systems, such as …

The purpose of this study was to develop a nanocarrier system for codelivery of paclitaxel
(PTX) and piperlongumine (PL) and investigate the therapeutic potential of improving …

Trilaurin-based solid lipid nanoparticles (TL-SLNs) containing paclitaxel (PTX) were
prepared by hot-melt high-pressure homogenisation and subsequent freezing and thawing …